Impact of extracellular protein binding on passive and active drug transport across Caco-2 cells

Pharmaceutical Research

Volumn 23, Issue 2, 2006, Pages 350-359

  Neuhoff, Sibylle ^a,b   Artursson, Per ^a   Zamora, Ismael ^c,d   Ungell, Anna Lena ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c Lead Molecular Design   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Apical efflux transporters; Basolateral uptake transporters; Caco 2 cell model; Extracellular protein binding; Intestinal secretion

Indexed keywords

BOVINE SERUM ALBUMIN; DIGOXIN; DOXORUBICIN; INOGATRAN; MANNITOL; METOPROLOL; PROPRANOLOL DERIVATIVE; QUINIDINE;

ACTIVE TRANSPORT; APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; CALCULATION; CELL MEMBRANE TRANSPORT; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DIFFUSION; DRUG MECHANISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR MIMICRY; PASSIVE TRANSPORT; PREDICTION; PRIORITY JOURNAL; TRANSPORT KINETICS; ULTRAFILTRATION;

ALGORITHMS; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD PROTEINS; CACO-2 CELLS; CATTLE; EXTRACELLULAR SPACE; HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; RADIOPHARMACEUTICALS; SERUM ALBUMIN, BOVINE;

EID: 32644436135     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11095-005-9304-3     Document Type: Article

References (26)

1. S. Yamashita T. Furubayashi M. Kataoka T. Sakane H. Sezaki H. Tokuda 2000 Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells Eur. J. Pharm. Sci. 10 195 204
2. P. Saha J. H. Kou 2002 Effect of bovine serum albumin on drug permeability estimation across Caco-2 monolayers Eur. J. Pharm. Biopharm. 54 319 324
3. P. Artursson 1990 Epithelial transport of drugs in cell culture. I: a model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells J. Pharm. Sci. 79 476 482
4. G. Wilson I. F. Hassan C. J. Dix I. Williamson R. Shah M. Mackay P. Artursson 1990 Transport and permeability properties of human Caco-2 cells: an in vitro model of the intestinal epithelial cell barrier J. Control. Release 11 25 40
5. G. Krishna K.-j. Chen C.-c. Lin A. A. Nomeir 2001 Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2 Int. J. Pharm. 222 77 89
6. M. E. Taub L. Kristensen S. Frokjaer 2002 Optimized conditions for MDCK permeability and turbidimetric solubility studies using compounds representative of BCS classes I-IV Eur. J. Pharm. Sci. 15 331 340
7. R. A. Walgren T. Walle 1999 The influence of plasma binding on absorption/exsorption in the Caco-2 model of human intestinal absorption J. Pharm. Pharmacol. 51 1037 1040
8. J. M. Fisher S. A. Wrighton J. C. Calamia D. D. Shen K. L. Kunze K. E. Thummel 1999 Midazolam metabolism by modified Caco-2 monolayers: effects of extracellular protein binding J. Pharmacol. Exp. Ther. 289 1143 1150
9. G. Colmenarejo 2003 In silico prediction of drug-binding strengths to human serum albumin Med. Res. Rev. 23 275 301
10. S. Neuhoff A.-L. Ungell I. Zamora P. Artursson 2003 pH-Dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions Pharm. Res. 20 1141 1148
11. A. L. Ungell J. Karlsson 2003 Cell cultures in drug discovery: an industrial perspective H. van De Waterbeemd H. Lennernäs P. Artursson Drug Bioavailability. Estimation of Solubility, Permeability, Absorption and Bioavailability Wiley-VCH Verlag GmbH & Co. KGaA Weinheim 90 131
12. L. Z. Benet S. Oie J. B. Schwartz 1996 Goodman & Gilman's: The Pharmacological Basis of Therapeutics McGraw-Hill New York
13. P. Artursson J. Karlsson 1991 Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells Biochem. Biophys. Res. Commun. 175 880 885
14. M. Rowland T. N. Tozer 1989 Clinical Pharmacokinetics. Concepts and Applications Lea and Febiger Philadelphia
15. Food and Drug Administration, U.S. Department of Health and Human Services, CDER. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. http://www.fda.gov/cder/guidance/ 3618fnl.pdf (2000).
16. S. Neuhoff A.-L. Ungell I. Zamora P. Artursson 2005 pH-Dependent passive and active transport of acidic drugs across Caco-2 cell monolayers Eur. J. Pharm. Sci. 25 211 220
17. J. Hunter B. H. Hirst N. L. Simmons 1991 Epithelial secretion of vinblastine by human intestinal adenocarcinoma cell (HCT-8 and T84) layers expressing P-glycoprotein Br. J. Cancer 64 437 444
18. Å. Frostell-Karlsson H. Widegren C. E. Green M. D. Hämäläinen L. Westerlund R. Karlsson K. Fenner H. van de Waterbeemd 2005 Biosensor analysis of the interaction between drug compounds and liposomes of different properties; a two-dimensional characterization tool for estimation of membrane absorption J. Pharm. Sci. 94 25 37
19. R. L. Lalonde D. M. Tenero B. S. Burlew V. L. Herring M. B. Bottorff 1990 Effects of age on the protein binding and disposition of propranolol stereoisomers Clin. Pharmacol. Ther. 47 447 455
20. T. J. Raub C. L. Barsuhn L. R. Williams D. E. Decker G. A. Sawada N. F. Ho 1993 Use of a biophysical-kinetic model to understand the roles of protein binding and membrane partitioning on passive diffusion of highly lipophilic molecules across cellular barriers J. Drug Target. 1 269 286
21. M. D. Troutman D. R. Thakker 2003 Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers Pharm. Res. 20 1200 1209
22. A. Seithel J. Karlsson C. Hilgendorf A. Björquist A. L. Ungell 2004 Variability in Gene Expression of Drug Transporters by Age and Passage in Caco-2 Cells EUFEPS Copenhagen
23. G. Englund, F. Rorsman, A. Rönnblom, L. Lazorova, A. Kindmark, and P. Artursson. Regional RNA expression of drug transporting proteins in the human gut. In 3rd World Conference on Drug Absorption, Transport and Delivery. Clinical Significance and Regulatory Impact. Barcelona, Spain (2005).
24. K. Westphal A. Weinbrenner T. Giessmann M. Stuhr G. Franke M. Zschiesche R. Oertel B. Terhaag H. K. Kroemer W. Siegmund 2000 Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein Clin. Pharmacol. Ther. 68 6 12
25. M. Verschraagen C. H. Koks J. H. Schellens J. H. Beijnen 1999 P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil Pharm. Res. 40 301 306
26. B. Angelin A. Arvidsson R. Dahlqvist A. Hedman K. Schenck-Gustafsson 1987 Quinidine reduces biliary clearance of digoxin in man Eur. J. Clin. Investig. 17 262 265